Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis

Journal of Applied Toxicology

Volumn 34, Issue 6, 2014, Pages 726-732

  Clarke, John D ^a   Sharapova, Tatiana ^b   Lake, April D ^a   Blomme, Eric ^b   Maher, Jonathan ^b   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b ABBVIE INC   (United States)

Author keywords

Biomarker; Liver toxicity; Methionine and choline deficient diet; MicroRNA 122; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINE; METHIONINE; MICRORNA 122; BIOLOGICAL MARKER; GENETIC MARKER; MICRORNA; MIRN122 MICRORNA, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHOLESTEROL METABOLISM; CLINICAL CHEMISTRY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; FATTY ACID METABOLISM; HISTOPATHOLOGY; HYPERTRANSAMINASEMIA; LIVER HISTOLOGY; LIVER HYPERPLASIA; LIVER INJURY; LIVER METABOLISM; LIVER TOXICITY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITAMIN DEFICIENCY; WEIGHT REDUCTION; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; GENETIC MARKER; GENETICS; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TIME;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; GENETIC MARKERS; MALE; METHIONINE; MICE, INBRED C57BL; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84899637173     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2960     Document Type: Article

References (29)

1. Ali R, Cusi K. 2009. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann. Med. 41: 265-278.
2. Amacher DE. 2011. The mechanistic basis for the induction of hepatic steatosis by xenobiotics. Expert Opin. Drug Metab. Toxicol. 7: 949-965.
3. Anstee QM, Goldin RD. 2006. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87: 1-16.
4. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. 2011. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108: 5003-5008.
5. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH, Sarrazin C, Herrmann E, Zeuzem S, Waidmann O, Piiper A. 2011. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 106: 1663-1669.
6. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. 2011. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6: e23937.
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. 2012. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023.
8. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM. 2004. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1: 106-113.
9. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA, Sanyal AJ. 2008. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48: 1810-1820.
10. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. 2009. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
11. Ding X, Ding J, Ning J, Yi F, Chen J, Zhao D, Zheng J, Liang Z, Hu Z, Du Q. 2012. Circulating microRNA-122 as a potential biomarker for liver injury. Mol. Med. Rep. 5: 1428-1432.
12. Elfimova N, Schlattjan M, Sowa JP, Dienes HP, Canbay A, Odenthal M. 2012. Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis. Front Physiol. 3: 476.
13. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3: 87-98.
14. Fan JG, Qiao L. 2009. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 8: 233-240.
15. Greenfield V, Cheung O, Sanyal AJ. 2008. Recent advances in nonalcholic fatty liver disease. Curr. Opin. Gastroenterol. 24: 320-327.
16. Hebbard L, George J. 2011. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8: 35-44.
17. James LP, Mayeux PR, Hinson JA. 2003. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 31: 1499-1506.
18. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 2002. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12: 735-739.
19. Osman A. 2012. MicroRNAs in health and disease--basic science and clinical applications. Clin. Lab. 58: 393-402.
20. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I, Beland FA. 2010. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab. Invest. 90: 1437-1446.
21. Reuben A. 2004. Hy's law. Hepatology 39: 574-578.
22. Schattenberg JM, Galle PR. 2010. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig. Dis. 28: 247-254.
23. Starkey Lewis PJ, Merz M, Couttet P, Grenet O, Dear J, Antoine DJ, Goldring C, Park BK, Moggs JG. 2012. Serum microRNA biomarkers for drug-induced liver injury. Clin. Pharmacol. Ther. 92: 291-293.
24. Stravitz RT, Sanyal AJ. 2003. Drug-induced steatohepatitis. Clin. Liver Dis. 7: 435-451.
25. Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, Beland FA, Rusyn I, Pogribny IP. 2012. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol. Appl. Pharmacol. 262: 52-59.
26. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, Kronenberger B, Piiper A. 2012. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J. Viral Hepat. 19: e58-e65.
27. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. 2009. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. U. S. A. 106: 4402-4407.
28. Watkins PB. 2011. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 89: 788-790.
29. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S. 2010. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 56: 1830-1838.